The innovation paradox: pharmaceutical marketing exclusivity and incentives for drug development
نویسندگان
چکیده
منابع مشابه
Using market-exclusivity incentives to promote pharmaceutical innovation.
The number of new drugs emerging in the U.S. pharmaceutical market is at a low point. The Food and Drug Administration (FDA) approved an average of 22.6 new drugs and biologics per year from 2005 through 2009, down from 37.2 a decade earlier (1995 through 1999). Paradoxically, this decrease in production has occurred despite billions of dollars in public and private funding for research and dev...
متن کاملMarket incentives and pharmaceutical innovation.
I study the impact of the Orphan Drug Act (ODA), which established tax incentives for rare disease drug development. I examine the flow of new clinical drug trials for a large set of rare diseases. Among more prevalent rare diseases, the ODA led to a significant and sustained increase in new trials. The impact for less prevalent rare diseases was limited to an increase in the stock of drugs. Ta...
متن کاملPrivate versus social incentives for pharmaceutical innovation.
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a model with a population of patients who can be treated with drugs that are horizontally and vertically...
متن کاملSex, gender, and pharmaceutical politics: From drug development to marketing.
BACKGROUND Biological sex differences and sociocultural gender norms affect the provision of health care products and services, but there has been little explicit analysis of the impact of sex differences and gender norms on the regulation of pharmaceutical development and marketing. OBJECTIVES This article provides an overview of the regulation of pharmaceuticals and examines the ways that r...
متن کاملBiosimilars, Data Exclusivity, and the Incentives for Innovation: A Critique of Kotlikoff’s White Paper
of America (PhRMA). The design, analysis, and composition of the analyses and manuscript were conducted independently and entirely by the authors, and we are solely responsible for any errors. The authors thank Professor Ernie Berndt of MIT for his review of this paper and several helpful suggestions.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical Health Services Research
سال: 2019
ISSN: 1759-8885,1759-8893
DOI: 10.1111/jphs.12288